It will commercialise two drug candidates based on research at Colorado University.
Ocugen, a Colorado-based startup, has signed a licensing agreement with Colorado University to continue development of two drug candidates for the treatment of rare eye diseases. One of the two candidates, OCU100, has already received orphan drug status from the US Food and Drug Administration (FDA).
OCU100 will be used to treat retinitis pigmentosa. The disease, for which there is currently no treatment, is an inherited, degenerative eye disease that causes severe vision impairment and often blindness. Although the disease…
